BR112013001863A2 - peptídeos com efeitos analgésicos e inibindo os canais asic. - Google Patents
peptídeos com efeitos analgésicos e inibindo os canais asic.Info
- Publication number
- BR112013001863A2 BR112013001863A2 BR112013001863A BR112013001863A BR112013001863A2 BR 112013001863 A2 BR112013001863 A2 BR 112013001863A2 BR 112013001863 A BR112013001863 A BR 112013001863A BR 112013001863 A BR112013001863 A BR 112013001863A BR 112013001863 A2 BR112013001863 A2 BR 112013001863A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- analgesic
- channels
- asic channels
- inhibiting
- Prior art date
Links
- 230000000202 analgesic effect Effects 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 108091006146 Channels Proteins 0.000 abstract 3
- 102000001671 Acid Sensing Ion Channels Human genes 0.000 abstract 1
- 108010068806 Acid Sensing Ion Channels Proteins 0.000 abstract 1
- 101500007657 Crotalus durissus terrificus Crotoxin chain gamma Proteins 0.000 abstract 1
- 241000272093 Dendroaspis Species 0.000 abstract 1
- 241000270295 Serpentes Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 239000002435 venom Substances 0.000 abstract 1
- 210000001048 venom Anatomy 0.000 abstract 1
- 231100000611 venom Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1003136A FR2963010B1 (fr) | 2010-07-26 | 2010-07-26 | Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic |
| PCT/FR2011/051800 WO2012022894A1 (fr) | 2010-07-26 | 2011-07-26 | Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013001863A2 true BR112013001863A2 (pt) | 2016-05-31 |
Family
ID=43589927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013001863A BR112013001863A2 (pt) | 2010-07-26 | 2011-07-26 | peptídeos com efeitos analgésicos e inibindo os canais asic. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8987207B2 (https=) |
| EP (1) | EP2598523B1 (https=) |
| JP (1) | JP6000245B2 (https=) |
| CN (1) | CN103097404B (https=) |
| AU (1) | AU2011290589A1 (https=) |
| BR (1) | BR112013001863A2 (https=) |
| CA (1) | CA2806471C (https=) |
| FR (1) | FR2963010B1 (https=) |
| MX (1) | MX336586B (https=) |
| RU (1) | RU2583299C2 (https=) |
| SG (1) | SG187877A1 (https=) |
| WO (1) | WO2012022894A1 (https=) |
| ZA (1) | ZA201300662B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105233286B (zh) * | 2015-09-10 | 2018-10-30 | 上海交通大学医学院 | 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途 |
| CN105412932B (zh) * | 2015-10-26 | 2019-08-16 | 上海交通大学医学院 | 含ASIC1a与RIP1结合抑制剂的制剂及其抑制神经元死亡的用途 |
| CN112717135A (zh) * | 2016-11-22 | 2021-04-30 | 上海交通大学医学院 | 酸敏感离子通道调控剂的用途 |
| CN107384952A (zh) * | 2017-08-23 | 2017-11-24 | 湖南甲骨文生物医药有限公司 | 用于筛选ASICs作用蛋白的酵母双杂交诱饵载体的构建方法 |
| AU2019449475A1 (en) * | 2019-06-04 | 2022-01-06 | Shanghaitech University | Affinity-maturated anti-ASIC1a antibodies |
| RU2768484C1 (ru) * | 2021-05-24 | 2022-03-24 | Закрытое акционерное общество "СКАЙ ЛТД" | Фармацевтическая композиция иммуностимулирующих веществ мурамилпептидной природы |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776896A (en) | 1996-01-03 | 1998-07-07 | Zeneca Limited | Analgesic peptides from venom of grammostola spatulata and use thereof |
| JP4959226B2 (ja) * | 2006-05-19 | 2012-06-20 | 独立行政法人産業技術総合研究所 | スリーフィンガー様蛋白質ライブラリ |
| JP2008193923A (ja) * | 2007-02-09 | 2008-08-28 | Janusys Kk | 蛋白質ライブラリ |
-
2010
- 2010-07-26 FR FR1003136A patent/FR2963010B1/fr not_active Expired - Fee Related
-
2011
- 2011-07-26 EP EP11752299.5A patent/EP2598523B1/fr active Active
- 2011-07-26 CA CA2806471A patent/CA2806471C/fr active Active
- 2011-07-26 JP JP2013521194A patent/JP6000245B2/ja active Active
- 2011-07-26 RU RU2013108262/10A patent/RU2583299C2/ru active
- 2011-07-26 US US13/812,457 patent/US8987207B2/en active Active
- 2011-07-26 MX MX2013001020A patent/MX336586B/es unknown
- 2011-07-26 WO PCT/FR2011/051800 patent/WO2012022894A1/fr not_active Ceased
- 2011-07-26 AU AU2011290589A patent/AU2011290589A1/en not_active Abandoned
- 2011-07-26 BR BR112013001863A patent/BR112013001863A2/pt not_active Application Discontinuation
- 2011-07-26 SG SG2013011705A patent/SG187877A1/en unknown
- 2011-07-26 CN CN201180043328.6A patent/CN103097404B/zh active Active
-
2013
- 2013-01-24 ZA ZA2013/00662A patent/ZA201300662B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2583299C2 (ru) | 2016-05-10 |
| RU2013108262A (ru) | 2014-09-10 |
| JP6000245B2 (ja) | 2016-09-28 |
| CN103097404A (zh) | 2013-05-08 |
| AU2011290589A1 (en) | 2013-03-07 |
| EP2598523B1 (fr) | 2015-09-09 |
| EP2598523A1 (fr) | 2013-06-05 |
| FR2963010B1 (fr) | 2014-08-15 |
| WO2012022894A1 (fr) | 2012-02-23 |
| US8987207B2 (en) | 2015-03-24 |
| WO2012022894A4 (fr) | 2012-04-12 |
| CA2806471C (fr) | 2020-07-07 |
| MX336586B (es) | 2016-01-21 |
| CA2806471A1 (fr) | 2012-02-23 |
| SG187877A1 (en) | 2013-03-28 |
| ZA201300662B (en) | 2013-09-25 |
| US20130196923A1 (en) | 2013-08-01 |
| MX2013001020A (es) | 2014-04-14 |
| JP2013535965A (ja) | 2013-09-19 |
| CN103097404B (zh) | 2015-09-16 |
| FR2963010A1 (fr) | 2012-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX374682B (es) | Moléculas de unión a 4-1bb. | |
| BR112013001863A2 (pt) | peptídeos com efeitos analgésicos e inibindo os canais asic. | |
| BR112015001690A2 (pt) | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) | |
| BR112016027585A2 (pt) | construções de anticorpo multiespecíficas | |
| BR112015010318A2 (pt) | Variantes de albumina | |
| BR112015014372A2 (pt) | inibidores de autotaxina | |
| BR112019012181A2 (pt) | enzimas polimerizantes para reações de sequenciamento | |
| MX2016001044A (es) | Aav variante y composiciones, metodos y usos para transferencia genica a celulas, organos y tejidos. | |
| MX2015012862A (es) | Moleculas de union para bcma y cd3. | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
| BR112017007202A2 (pt) | receptores de célula t | |
| BR112015005466A2 (pt) | proteínas de domínio scaffold à base de fibronectina que se ligam à miostatina | |
| BR112012029588A2 (pt) | materiais biológicas relacionados a her3. | |
| MX2013007716A (es) | Sistemas de expresion. | |
| ECSP14004893A (es) | Moléculas de unión para bcma y cd3 | |
| BR112018008746A8 (pt) | composições e métodos para a inibição de atividade de arginase | |
| BR112014018679A2 (pt) | variantes de albumina | |
| BR112016030424A2 (pt) | construções de anticorpo multiespecíficas | |
| BR112015008708A2 (pt) | composição para clivagem de dna alvo compreendendo um rna guia específico para o dna alvo e ácido nucleico que codifica proteína cas ou proteína cas e uso da mesma | |
| EP4667583A3 (en) | Multiple tagging of long dna fragments | |
| CL2011002664A1 (es) | Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4. | |
| MX2019008803A (es) | Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos. | |
| EP2576839A4 (en) | NUCLEIC ACID STATEMENT AND QUANTIFICATION BY POSTHYBRIDISING LABELING AND UNIVERSAL ENCODING | |
| BR112014024282A2 (pt) | anticorpos ligantes ao receptor b1 da bradicinina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notice of approval relating to section 229 industrial property law | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |